Cobra Biologics and KAHR Medical extend partnership

27-Jun-2012

To develop treatment for cancer and autoimmune diseases

Cobra Biologics, a manufacturer of biologics and pharmaceuticals, has announced a continuation of its partnership with KAHR Medical, based in Jerusalem, Israel.

KAHR is a developer of novel drugs based on Signal Converter Proteins (SCP) technology for the treatment of cancer and autoimmune diseases.

The extended collaboration will allow Cobra Biologics to advance KAHR-101 and KAHR-102 for future pre-clinical and clinical testing using Cobra Biologics’ maxXpress service.

Sign up for your free email newsletter

Cobra Biologics will also be carrying out the process development and scale-up for the GMP production of KAHR-101 and KAHR-102.

Companies

Featured Companies

Related Content

How will COVID-19 accelerate vaccine development? Part II
How will COVID-19 accelerate vaccine development? Part II
CombiGene and Cobra sign agreement for GMP plasmid production
CombiGene and Cobra sign agreement for GMP plasmid production
Research partnership removes bottleneck from AAV development
Research partnership removes bottleneck from AAV development
Cobra Biologics and Symbiosis complete $6m collaboration
Cobra Biologics and Symbiosis complete $6m collaboration
CGT Catapult addresses skills gap with apprenticeship programme for advanced therapies
CGT Catapult addresses skills gap with apprenticeship programme for advanced therapies
A closer look at the Queen's Enterprise Award winners
A closer look at the Queen's Enterprise Award winners
Cobra begins £15m gene therapy manufacturing expansion
Cobra begins £15m gene therapy manufacturing expansion
NEUWAY Pharma and Cobra Biologics collaborate to develop GMP-grade engineered protein capsules (EPCs) manufacturing process
NEUWAY Pharma and Cobra Biologics collaborate to develop GMP-grade engineered protein capsules (EPCs) manufacturing process
Cobra Biologics and Alligator Bioscience extend drug development partnership
Cobra Biologics and Alligator Bioscience extend drug development partnership
Cobra Biologics and Touchlight link up to optimise manufacture of gene therapies
Cobra Biologics and Touchlight link up to optimise manufacture of gene therapies
Cobra Biologics links up with CPI in £1.8m project to advance development of regenerative medicines
Cobra Biologics links up with CPI in £1.8m project to advance development of regenerative medicines
Alligator Bioscience benefits from Cobra’s maxXpress platform
Alligator Bioscience benefits from Cobra’s maxXpress platform
Cobra and Tecrea win Innovate UK grant
Cobra and Tecrea win Innovate UK grant
GMP certification boost for Cobra Biologics
GMP certification boost for Cobra Biologics
Interview: Focused and determined
Interview: Focused and determined
Cobra Biologics expands antibody GMP production capacity
Cobra Biologics expands antibody GMP production capacity